№ files_lp_4_process_3_115185
File format: docx
Character count: 308
File size: 118 KB
Flowchart illustrating clinical decision-making for the management of recurrent brain metastasis following previous radiotherapy interventions.
Year:
2026
Region / City:
Not specified
Subject:
Oncology, Neuroscience
Document Type:
Supplementary Figure
Institution:
Not specified
Author:
Not specified
Target Audience:
Medical professionals, researchers
Treatment Methods:
SRS, FSRS, BT, HA-WBRT, WBRT
Clinical Focus:
Recurrent brain metastasis
Anatomical Focus:
Central Nervous System
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2026
Region / City:
Aberdeen, UK
Subject:
Clinical trial coordination for colorectal liver metastasis
Document Type:
Agreement
Organization / Institution:
NHS Grampian / University of Aberdeen Medical School
Partner Institution:
[Redacted hospital department]
Authors / Signatories:
Coordinating Centre, Partner Institution representatives
Target Audience:
Clinical researchers and trial coordinators
Effective Date:
[Redacted]
Trial Name:
LORDS-M
Regulatory Compliance:
GDPR, GCP, PIPL, Data Security Law, Declaration of Helsinki 1996
Responsibilities:
Coordination of trial, data handling, adherence to protocol
Trial Phase:
Observational / Audit
Year:
2026
Region / City:
Not specified
Topic:
Breast cancer patient characteristics and outcomes
Document Type:
Supplementary data tables
Institution / Organization:
Not specified
Author:
Not specified
Study Population:
Patients with carcinoma in situ and invasive carcinoma
Sample Size:
491
Clinical Parameters:
Age, tumor size, molecular typing, type of surgery, lymph node status
Imaging Parameters:
Ultrasonography (US), Mammography, BI-RADS categories, calcification
Follow-up Period:
Not specified
Recurrence and Metastasis Analysis:
Univariate proportional hazard analysis
Data Collection Methods:
Clinical examination, pathologic evaluation, imaging studies
Year:
2026
Region / City:
N/A
Subject:
Oncology, Urology
Document Type:
Case Report
Organization / Institution:
N/A
Author:
Alhilaly S, Elbaz R, Khan I
Target Audience:
Healthcare professionals, researchers in urology and oncology
Period of validity:
N/A
Approval Date:
N/A
Date of amendments:
N/A
Year:
2026
Institution:
Orthopaedic outpatient clinic
Document type:
Medical case report
Authors:
Multiple, corresponding author indicated
Patient age:
40
Patient gender:
Male
Patient smoking status:
Smoker
Medical condition:
Recurrent giant-cell tumor of proximal humerus with pulmonary metastasis
Procedures:
Wide excision, hemiarthroplasty using Austin Moore prosthesis
Histopathology results:
Postoperative biopsy showed recurrent giant-cell tumor, no sign of malignancy initially; malignant GCT after shoulder disarticulation
Infection:
S. aureus, treated with specific antibiotics
Consent:
Informed consent obtained from patient
Follow-up outcome:
Patient deceased 2 years post-disarticulation due to loss of follow-up and missed chemotherapy
Imaging:
X-ray, CT scans partially performed, some unavailable
References:
Added discussion and references following JKKI style
Year:
2013
Region / city:
Not specified
Topic:
Breast cancer, radiotherapy, surgical procedures
Document type:
Audit report
Organization / institution:
Not specified
Author:
Dr John McGrane
Target audience:
Radiotherapy professionals, surgical teams, oncology departments
Period of validity:
Not specified
Approval date:
28 April 2013
Date of last review:
16 April 2018
Organisation:
NHS Greater Glasgow & Clyde
Department:
Radiotherapy Physics, Department of Clinical Physics and Bioengineering (DCPB)
Location:
Beatson West of Scotland Cancer Centre, Gartnavel General Hospital, Glasgow; Monklands Hospital, Airdrie
Directorate:
Diagnostic Directorate, Acute Services Division
Job Title:
Scientific Lead (Clinical Planning & Imaging)
Reports to:
Consultant Clinical Physicist, Deputy Head of Radiotherapy Physics
Accountable to:
Chief Executive via General Manager of Diagnostics Directorate
Type of Document:
Job Description
Service Area:
Radiotherapy Physics
Staff Responsibility:
Clinical Physicists, Planning Services Manager, Dosimetrists, Head of Treatment Planning/Imaging
Regulatory Framework:
Ionising Radiation Regulations (2017); Ionising Radiation (Medical Exposures) Regulations (2017); ISO 9001 Quality Management System
Clinical Scope:
External Beam Radiotherapy, Treatment Planning, Radiotherapy Imaging, Dosimetry, Quality Assurance
Equipment:
Linear accelerators, CT simulators, treatment simulators, verification systems, low energy x-ray treatment unit
Associated Institution:
University of Glasgow
Year:
2023
Region / City:
Middlesbrough
Subject:
Urgent and palliative radiotherapy
Document Type:
Referral form
Institution:
James Cook University Hospital
Author:
Unknown
Target Audience:
Medical professionals involved in patient referrals for radiotherapy
Period of Validity:
Ongoing
Approval Date:
Unknown
Date of Changes:
Unknown
Year:
2013
Region / City:
Not specified
Topic:
Breast Cancer, Radiotherapy
Document Type:
Audit Report
Organization / Institution:
Not specified
Author:
Dr. John McGrane
Target Audience:
Oncology, Surgical Teams, Radiotherapy Staff
Period of Action:
Not specified
Approval Date:
Sunday 28 April 2013
Last Reviewed Date:
Thursday 2 May 2024
Context:
This is an audit report on the rates of surgical clip insertion for tumour bed localisation in patients undergoing whole breast radiotherapy after breast conserving surgery.
Year:
2021
Region / city:
India
Topic:
Prostate Cancer Radiation Therapy
Document type:
Survey
Organization / institution:
N/A
Author:
N/A
Target audience:
Radiation Therapists
Effective period:
N/A
Approval date:
N/A
Date of amendments:
N/A
Year:
2020
Region / City:
Not specified
Subject:
Bladder cancer, radical radiotherapy, cystoscopy
Document Type:
Audit Template
Organization:
Not specified
Author:
Dr. Richard Walshaw, Dr. Tony Elliott
Target Audience:
Urologists, Radiotherapy professionals, Clinical Nurse Specialists
Period of Action:
Not specified
Approval Date:
14 March 2020
Review Date:
22 May 2020
Year:
2016
Region / City:
Canada
Subject:
Radiotherapy, CyberKnife Technology, Technical Quality Control
Document Type:
Guidance document
Organizations:
Canadian Association of Radiation Oncology, Canadian Organization of Medical Physicists, Canadian Association of Medical Radiation Technologists, Canadian Partnership Against Cancer
Author(s):
Eric Vandervoort, Horacio Patrocinio, Tom Chow, Emilie Soisson, Dominic Béliveau Nadeau
Target Audience:
Medical physicists, radiation oncologists, radiation technologists
Effective Period:
Ongoing from 2016
Approval Date:
April 15, 2016
Version:
CKT.2015.04.15
Website:
www.cpqr.ca
Description:
Guidance document providing detailed performance objectives and safety criteria for CyberKnife stereotactic radiosurgery, including daily quality control tests and system specifications.
Year:
2019
Region / City:
Galway, Ireland
Topic:
Job Description
Document Type:
Job Specification
Organization:
Saolta University Health Care Group
Author:
Saolta University Health Care Group
Target Audience:
Professionals in Radiotherapy
Effective Date:
Not specified
Amendment Date:
Not specified
Date:
14 December 2018
Location:
Het Nieuwe Instituut, Museumpark 25, 3015 CB Rotterdam
Additional location:
Erasmus University, Burgemeester Oudlaan 50, 3062 PA Rotterdam
Event type:
Scientific symposium program
Main theme:
High Precision Radiotherapy
Occasion:
Inauguration of Prof. Dr. M. S. Hoogeman
Organizing institution:
Erasmus MC Rotterdam
Moderator (morning):
Prof. Dr. B. Heijmen, Erasmus MC Rotterdam
Moderator (afternoon):
Prof. Dr. M. van Vulpen, HollandPTC Delft
Participating institutions:
Erasmus MC Rotterdam; LUMC Leiden; HollandPTC Delft; Maastro Maastricht; Delft University of Technology; VUmc Amsterdam
Topics:
Molecular Radiomics; Biological Image Guided Radiotherapy; Automation in Radiotherapy; Proton Therapy; Artificial Intelligence in Radiotherapy; Robust Proton Therapy
Program structure:
Lectures, discussions, lunch, inauguration ceremony
Year:
2023-2024
Organization:
Radiotherapy UK
Type of document:
Impact report
Location:
United Kingdom
Author:
Sarah Quinlan MBE
Chair:
Professor Pat Price
Patron:
Bryan Robson OBE
Target audience:
UK cancer patients, policymakers, healthcare professionals
Campaigns:
#Radiotherapy4Life, #CatchUpWithCancer
Launch date:
2010
Period covered:
2023-2024
Publication references:
The Lancet Oncology, UKIO, OPC, ESTRO
Main focus:
Access to radiotherapy, healthcare inequalities, patient advocacy
Year:
2012
Region / City:
Europe / Vienna
Theme:
Lung Cancer, Oncology
Document Type:
Survey
Organization / Institution:
European Society for Medical Oncology (ESMO)
Author:
Dr. Raffaele Califano
Target Audience:
Medical Oncologists, Radiation Oncologists
Period of Action:
Deadline end of February 2012
Approval Date:
N/A
Date of Changes:
N/A
Year:
2018
Region / City:
United Kingdom
Subject:
Advanced radiotherapy technologies and clinical research
Document type:
Research network announcement
Organization / Institution:
Cancer Research UK, Institute of Cancer Research, Leeds Teaching Hospitals NHS Trust, University of Leeds, University of Manchester, The Christie NHS Foundation Trust, University of Oxford, The Royal Marsden NHS Foundation Trust, University College London
Authors:
Kevin Harrington, Emma Hall, Maria Hawkins, Ann Henry, Ranald MacKay, Tim Maughan, Angela McDonald, Chris Nutting, Uwe Oelfke, David Sebag-Montefiore, Ricky A. Sharma, Marcel van Herk, Corinne Faivre-Finn
Funding:
Cancer Research UK Network Accelerator Award (£4.3 million)
Target audience:
Clinical researchers, oncologists, medical physicists, health economists
Technologies:
SABR, MR-Linac, Proton Beam Therapy (PBT), IMRT
Focus areas:
Prostate, rectal, lung, oesophageal, and central nervous system cancers
Purpose:
Coordination of research, development of clinical protocols, and multi-centre collaboration
Start date:
2018
Description:
Peer-reviewed publication presenting the establishment and goals of a UK-wide collaborative network for implementing advanced radiotherapy technologies, detailing participating centers, methodologies, and focus on hypofractionated treatment regimens.
Protocol version:
6.0
Date:
18 September 2020
Study name:
rEECur
Study design:
International randomised controlled trial
Medical condition:
Recurrent and primary refractory Ewing sarcoma
Intervention:
Chemotherapy
Sponsor:
University of Birmingham
Sponsor protocol number:
RG_13-277
CRCTU number:
SA2015
EudraCT number:
2014-000259-99
ISRCTN reference number:
ISRCTN36453794
Chief Investigator:
Dr Martin McCabe
Coordinating institution:
Cancer Research UK Clinical Trials Unit, University of Birmingham
Geographic scope:
International
Participating regions:
United Kingdom, Germany, Italy, France, Spain, Scandinavia, Australia, New Zealand, Switzerland
Target population:
Patients with recurrent or primary refractory Ewing sarcoma
Regulatory status:
Ethics and regulatory approval required per participating country
Amendment history:
Substantial amendments between 2014 and 2016
Document type:
Clinical trial protocol
Randomisation method:
Centralised online randomisation
Trial phase:
Phase II (Germany-specific limitation noted)
Year:
2024
Region / city:
Global
Theme:
Oncology, Endometrial Cancer, Pharmaceutical Submissions
Document Type:
Medical Submission
Organization / Institution:
AstraZeneca Pty Ltd
Author:
AstraZeneca Pty Ltd
Target Audience:
Medical professionals, regulatory bodies, pharmaceutical companies
Period of validity:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified
Year:
2022
Country:
Australia
Therapeutic area:
Oncology
Disease:
Endometrial cancer
Biomarker status:
Mismatch repair deficient (dMMR)
Medicine name:
Dostarlimab
Brand name:
Jemperli
Dosage form:
Solution concentrate for intravenous infusion
Sponsor:
GlaxoSmithKline Australia Pty Ltd
Regulatory body:
Pharmaceutical Benefits Advisory Committee
Submission type:
Standard Re-entry submission
Requested listing:
Section 100
Comparator treatments:
Standard of care chemotherapy; pembrolizumab plus lenvatinib; pembrolizumab monotherapy
Clinical trial referenced:
GARNET
Approval status:
Provisional approval
Indication:
Recurrent or advanced endometrial cancer after platinum-containing regimen
Decision context:
PBS listing consideration
Period covered:
Up to November 2022
Year:
2023
Region / city:
Aarhus, Denmark
Topic:
Psychiatry, Genetics
Document Type:
Research Supplement
Institution:
iPSYCH Research Initiative, Aarhus University
Author:
iPSYCH Investigators
Target Audience:
Researchers, Geneticists, Psychiatrists
Period of validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified